• 1
    Savige J, Gillis D, Benson E et al. (1999) International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 111, 50713.
  • 2
    Jennette JC, Falk RJ (1995) Clinical and pathological classification of ANCA-associated vasculitis: what are the controversies? Clin Exp Immunol 101(Suppl 1), 1822.
  • 3
    Hellmich B, Gross WL (2004) Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 5, 2535.
  • 4
    Klion AD, Bochner BS, Gleich GJ et al. (2006) Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117, 1292302.
  • 5
    Keogh KA, Specks U (2006) Churg-Strauss syndrome: update on clinical, laboratory and therapeutic aspects. Sarcoidosis Vasc Diffuse Lung Dis 23, 312.
  • 6
    Yamauchi K, Sasaki N, Niisato M et al. (2010) Analysis of pulmonary allergic vasculitis with eosinophil infiltration in asthma model of mice. Exp Lung Res 36, 22736.
  • 7
    Druker BJ, Talpaz M, Resta DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 10317.
  • 8
    Druker BJ, Sawyers CL, Kantarjian H et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344, 103842.
  • 9
    Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347, 47280.
  • 10
    van Oosterom AT, Judson I, Verweij J et al. (2001) European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 14213.
  • 11
    Druker BJ, Tamura S, Buchdunger E et al. (1996) Effects of s selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 2, 5616.
  • 12
    Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79, 1283316.
  • 13
    Bonner JC (2004) Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 15, 25573.
  • 14
    Ohkawara Y, Lei XF, Stampfli MR, Marshall JS, Xing Z, Jordana M (1997) Cytokine and eosinophil responses in the lung, peripheral blood and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am J Respir Cell Mol Biol 16, 51020.
  • 15
    Bullwinkel J, Baron-Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, Scholzen T (2006) Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 206, 62435.
  • 16
    Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH (2002) Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359, 15778.
  • 17
    Cools J, DeAngelo DJ, Gotlib J et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348, 120114.
  • 18
    Pardanani AD, Elliott MA, Reeder TL et al. (2003) Imatinib therapy for systemic mast cell disease. Lancet 362, 5356.
  • 19
    Pardanani AD, Reeder TL, Porrata LF et al. (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101, 33917.
  • 20
    Cortes J, Ault P, Koller C et al. (2003) Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101, 471416.
  • 21
    Ishida-Okawara A, Ito-Ihara T, Muso E et al. (2004) Neutrophil contribution to the crescentic glomerulonephritis in SCG/Kj mice. Nephrol Dial Transplant 19, 170815.
  • 22
    Yamaguchi Y, Suda T, Suda J et al. (1988) Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursers. J Exp Med 167, 4356.
  • 23
    Clutterbuck EJ, Hirst EM, Sanderson CJ (1989) Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73, 150412.
  • 24
    Oliveira SH, Taub DD, Nagel J et al. (2002) Stem cell factor induces eosinophil activation and degranulation: mediator release and gene array analysis. Blood 100, 42917.
  • 25
    Kobayashi H (1993) Effect of c-kit ligand (stem cell factor) in combination with interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3, on eosinophil lineage. Int J Hematol 58, 216.
  • 26
    Yuan Q, Austen KF, Friend DS, Heidtman M, Boyce JA (1997) Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4)–mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J Exp Med 186, 31323.
  • 27
    Bach MK, Brashler JR, Stout BK et al. (1992) Activation of human eosinophils by platelet-derived growth factor. Int Arch Allergy Immunol 97, 1219.
  • 28
    Heldin CH, Ostman A, Ronnstrand L (1998) Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378, F79113.
  • 29
    Kingsley K, Huff JL, Rust WL et al. (2002) ERK1/2 mediates PDGF-BB stimulated vascular smooth muscle cell proliferation and migration on laminin-5. Biochem Biophys Res Commun 293, 10006.
  • 30
    Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284, L82633.
  • 31
    Schultz K, Fanburg BL, Beasley D (2006) Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 290, H252834.
  • 32
    Dahal BK, Heuchel R, Pullamsetti SS et al. (2011) Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β. Pulm Circ 1, 25968.
  • 33
    Abdollahi A, Li M, Ping G et al. (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201, 92535.
  • 34
    Aono Y, Nishioka Y, Inayama M et al. (2005) Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171, 127985.
  • 35
    Daniels CE, Wilkes MC, Edens M et al. (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114, 130816.